Literature DB >> 21207010

[Drug therapy options for oligoasthenoteratozoospermia syndrome].

M Trottmann1, F M Köhn, M Dickmann, C G Stief, A J Becker.   

Abstract

Medical treatment of oligoasthenoteratozoospermia (OAT) syndrome includes many different treatment concepts. The targeted causes in the treatment of OAT syndrome are either hormonal, as for example hypothalamic, pituary, or, seldom, hyperprolactinemic disturbances, or acute or chronic urogenital infections, as well as ejaculatory disorders. Often no pathogenic reason for OAT syndrome can be found and targeted. Most treatment concepts in the past tried to improve sperm quality. Administration of antiestrogens, antioxidants, hormones, and micronutrients has been tried and used to improve sperm quality. The present article provides an overview of current medical treatment options for OAT syndrome, including former unsuccessful treatment concepts. The article furthermore sketches out potential treatment options, which might be available in the future.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21207010     DOI: 10.1007/s00120-010-2437-y

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  90 in total

1.  Ketotifen improves sperm motility and sperm morphology in male patients with leukocytospermia and unexplained infertility.

Authors:  Alejandro Oliva; Luc Multigner
Journal:  Fertil Steril       Date:  2006-01       Impact factor: 7.329

Review 2.  The role of antisperm antibodies during fertilization and for immunological infertility.

Authors:  Claudia Bohring; Walter Krause
Journal:  Chem Immunol Allergy       Date:  2005

3.  Hormonal effects of tamoxifen in oligospermic men.

Authors:  K J Willis; D R London; M A Bevis; W R Butt; S S Lynch; G Holder
Journal:  J Endocrinol       Date:  1977-04       Impact factor: 4.286

4.  Placebo-controlled, double-blind, cross-over trial of glutathione therapy in male infertility.

Authors:  A Lenzi; F Culasso; L Gandini; F Lombardo; F Dondero
Journal:  Hum Reprod       Date:  1993-10       Impact factor: 6.918

5.  Seminal plasma cobalamin significantly correlates with sperm concentration in men undergoing IVF or ICSI procedures.

Authors:  Jolanda C Boxmeer; Marij Smit; Robertus F Weber; Jan Lindemans; Johannes C Romijn; Marinus J Eijkemans; Nicholas S Macklon; Regine P Steegers-Theunissen
Journal:  J Androl       Date:  2007-02-07

6.  Lack of effect of a single i.v. dose of oxytocin on sperm output in severely oligozoospermic men.

Authors:  Maria M Byrne; Claus Rolf; Marion Depenbusch; Trevor G Cooper; Eberhard Nieschlag
Journal:  Hum Reprod       Date:  2003-10       Impact factor: 6.918

7.  Combination clomiphene citrate and antioxidant therapy for idiopathic male infertility: a randomized controlled trial.

Authors:  Hussein Ghanem; Osama Shaeer; Amgad El-Segini
Journal:  Fertil Steril       Date:  2009-03-06       Impact factor: 7.329

8.  Increase of oxidative stress in human sperm with lower motility.

Authors:  Shu-Huei Kao; Hsiang-Tai Chao; Haw-Wen Chen; Thomas I S Hwang; Tien-Ling Liao; Yau-Huei Wei
Journal:  Fertil Steril       Date:  2007-07-31       Impact factor: 7.329

Review 9.  Coenzyme Q10 and male infertility.

Authors:  G Balercia; A Mancini; F Paggi; L Tiano; A Pontecorvi; M Boscaro; A Lenzi; G P Littarru
Journal:  J Endocrinol Invest       Date:  2009-05-21       Impact factor: 4.256

Review 10.  WITHDRAWN: Bromocriptine for idiopathic oligo/asthenospermia.

Authors:  P Vandekerckhove; R Lilford; A Vail; E Hughes
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18
View more
  1 in total

1.  In vitro effects of zinc, D-aspartic acid, and coenzyme-Q10 on sperm function.

Authors:  Filippo Giacone; Rosita A Condorelli; Laura M Mongioì; Valentina Bullara; Sandro La Vignera; Aldo E Calogero
Journal:  Endocrine       Date:  2016-07-15       Impact factor: 3.633

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.